~~<i id='BD0DD6EA90'><strike id='BD0DD6EA90'><tt id='BD0DD6EA90'><pre id='BD0DD6EA90'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：knowledge 2025-10-01 00:30:39 Page View：4

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FTC loses bid to block Novant's North Carolina hospital merger
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

explore

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

ThisphotoprovidedbySamsungC&TCorp.showsgiantpandaAiBaoandhertwincubsatanamusementparkinYongin,SouthK

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Structure Therapeutics oral GLP

DrewAngerer/GettyImagesStructureTherapeuticsreportedMondaythatitsoralGLP-1drugledtoweightlossintwosm